Sinovant Sciences is set up to take an integrated approach to develop a drug from Phase I all the way to approval.
In Conversation
From the very beginning Helsinn took a very long-term, step-by-step approach when it came to entering the China market.
Investors want to invest in the right place and we are the right place. We have a very strong and persistent capability for innovation
For patients suffering from genetic diseases in China, the frequent and chronic healthcare models that we see in the US and EU may not work
Today, we are the world’s second-largest pharma market. I hope that in a decade or two, China will also become the world’s second-most innovative pharma market
While the Chinese pharma landscape has developed very rapidly over the past few years, we still see a split within the industry between very commercial-based and…
When we first started, domestic products in the stent market had a very small market share. By the end of 2006, we had over 60 percent…
Cell and gene therapy is an extremely complex area and unlike pharmaceutical drugs, there tends to be a lot of process-specific know-how and manual expertise required.
Unlike big companies that seek to grow by acquiring small innovative companies, HEUFT grows organically.
Our work at Absea over the past 18 years has already proven our track record in antibody development and production, and I believe it is now…
Whether you look at it from a socioeconomic or personal perspective, HIV is a hugely significant therapeutic area with highly unmet medical needs.
A company with two main operating sites has to find the best operating model. Oncologie is not simply a company headquartered in the US with a…
